Drugs - MedicineNews.net - Medical Updates

Search results for "Renal cell carcinoma"

Nivolumab plus Ipilimumab has shown continued survival benefit at 42-month follow-up in patients with previously untreated advanced or metastatic renal cell carcinoma

Updated results from the phase 3 CheckMate -214 study evaluating the combination of Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) versus Sunitinib( Sutent ) in patients with previously untreated adv ... read article

Tivozanib in combination with Nivolumab in renal cell carcinoma: interim results from phase 2 portion of the TiNivo trial

Updated interim results from the phase 2 portion of the TiNivo study, a phase 1b/2 multicenter trial of oral Tivozanib ( Fotivda ) in combination with intravenous Nivolumab ( Opdivo ), an immune check ... read article

Tivozanib, a VEGF tyrosine kinase inhibitor, for the treatment of adult patients with advanced renal cell carcinoma

Tivozanib ( Fotivda ) is an oral, once-daily, vascular endothelial growth factor ( VEGF ) tyrosine kinase inhibitor ( TKI ) for the treatment of adult patients with advanced renal cell carcinoma ( RCC ... read article

Mvasi, a biosimilar to the cancer drug Avastin, approved from FDA for certain colorectal, lung, brain, kidney and cervical cancers

The FDA ( Food and Drug Administration ) has approved Mvasi ( Bevacizumab-awwb ) as a biosimilar to Avastin ( Bevacizumab ) for the treatment of multiple types of cancer. Mvasi is the first biosimil ... read article

Association found between renal cell cancinoma and long-term use of non-Aspirin anti-inflammatory drugs

Long-term use of non-Aspirin anti-inflammatory drugs ( NSAIDs ) is associated with an increased risk of renal cell cancer ( RCC ).In the United States, kidney cancer is the seventh leading type of can ... read article

FDA: Afinitor approved for subependymal giant cell astrocytoma associated with tuberous sclerosis

The FDA ( Food and Drug Administration ) has granted accelerated approval to Everolimus ( Afinitor ), an mTOR inhibitor, for patients with subependymal giant cell astrocytoma ( SEGA ) associated with ... read article

Votrient in the treatment of advanced renal cell carcinoma and ovarian carcinoma

GlaxoSmithKline ( GSK ) has announced results from ongoing Phase II studies of Pazopanib ( Votrient ) in advanced or metastatic renal cell carcinoma ( RCC ) and ovarian cancer. Pazopanib is an ora ... read article

New indication for Afinitor: treatment of patients with subependymal giant cell astrocytoma associated with tuberous sclerosis

The FDA ( Food and Drug Administration ) approved Afinitor ( Everolimus ) to treat patients with subependymal giant cell astrocytoma ( SEGA ) associated with tuberous sclerosis, a rare genetic disorde ... read article

Management of renal cell cancer

Renal cell carcinoma ( RCC ) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy. In contrast ... read article

Renal cell carcinoma: interventional cryoablation is effective

Freezing kidney tumors should be the gold standard or first treatment option for all individuals with tumors that are 4 centimeters in size or smaller. And, this treatment, interventional cryoablation ... read article

Advanced kidney cancer: Sunitinib shows promising results in patients with poor prognosis

Sunitinib ( Sutent ) prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer ( metastatic renal cell carcinoma ) patients with a poor prognosis such as ... read article

Advanced kidney cancer: Sunitinib shows promising results in patients with poor prognosis

Advanced form of kidney cancer: Votrient approved

The FDA ( Food and Drug Administration ) has approved Votrient ( Pazopanib ), the sixth drug to be approved for kidney cancer since 2005. Votrient is an oral medication that interferes with angioge ... read article

Microangiopathic hemolytic anemia in patients treated with Bevacizumab plus Sunitinib

The safety and maximum tolerated dose ( MTD ) of Sunitinib malate( Sutent ) in combination with Bevacizumab ( Avastin ) has been assessed in patients with metastatic renal cell carcinoma ( mRCC ) in a ... read article

Sorafenib: older renal cancer patients appear to benefit from treatment

Older and younger patients with renal cancer derive similar benefit from Sorafenib ( Nexavar ) therapy and tolerate the drug equally well. Although the risk of being diagnosed with cancer increase ... read article

Focus

Multiple sclerosis: FDA has approved Tecfidera

The FDA ( Food and Drug Administration ) has approved Tecfidera ( Dimethyl fumarate ) capsules to treat adults with relapsing forms of multiple sclerosis.Multiple sclerosis is a chronic, inflammatory, ... read article

Apremilast linked to significant and clinically meaningful improvements for the primary and major secondary endpoint in plaque psoriasis

Celgene has announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase ... read article

Kadcyla, a new treatment for late-stage breast cancer, approved by Food and Drug Administration

The U.S. Food and Drug Administration ) has approved Kadcyla ( Ado-Trastuzumab Emtansine ), a new therapy for patients with HER2-positive, late-stage ( metastatic ) breast cancer.HER2 is a protein inv ... read article

FISSION and NEUTRINO trial: Sofosbuvir has met primary endpoints for hepatitis C

Results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide Sofosbuvir in combination with Ribavirin ( FISSION ) and in combination with Ribavirin ... read article

Increased risk of high-grade prostate cancer with 5-alpha reductase inhibitors

Men aged 55 and over with a normal digital rectal examination and PSA less than or equal to 3.0 ng/mL at baseline taking Finasteride 5 mg/day ( 5 times the dose of Propecia ) in the 7-year Prostate Ca ... read article

Castration-resistant prostate cancer: Cabozantinib linked to high rates of complete or partial bone scan resolution, pain relief, improvements in hemoglobin, and tumor regression

Exelixis has reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer ( CRPC ) treated with Cabozantinib ( XL184; Cometriq ) in an ongoing phase 2 ... read article